MorphImmune, Inc. Appoints Ronald Martell as President and CEO

SAN FRANCISCO: SAN FRANCISCO, June 2, 2021 /PRNewswire/ -- MorphImmune, Inc., a private platform company that is advancing a highly specific targeting technology that uses a ligand-linked payload to reprogram the immune system, announced the appointment of Ronald Martell as the company's President and CEO effective April 12, 2021. A...

Click to view original post